

3pbiovian.com | business@3pbiovian.com

Press Release

12/02/2025

3PBIOVIAN Celebrates Its First Anniversary Leading the Future of Biotechnology

Pamplona–Turku, 12 February 2025

3PBIOVIAN is pleased to celebrate its first anniversary, marking 12 months of growth, transformation, and innovation in the biopharmaceutical and advanced therapies industry.

Founded in 2024 through the combination of BIOVIAN and 3P Biopharmaceuticals, two leading CDMO with a solid track record in the biotech and advanced therapies industries, 3PBIOVIAN was created to offer comprehensive and innovative solutions to clients across the global biopharmaceutical landscape.

With two manufacturing plants located in Noáin (Navarre) and Turku (Finland), 3PBIOVIAN offers a full spectrum of capabilities to meet the diverse process development and manufacturing needs of new medicines for its clients: from recombinant proteins and monoclonal antibodies to plasmids and advanced therapies.

The company views this first year as a period of learning, growth, and expansion. In just 12 months, 3PBIOVIAN has gained the trust of numerous new clients who have selected the company as their ideal partner for both protein and advanced therapy projects, while also strengthening its relationships with long-time collaborators. This growth has positioned 3PBIOVIAN as a key player in the global development of new medicines for the biotechnology industry.

Driving the company's growth is a team of more than 500 highly skilled professionals working at both locations. In the words of Dámaso Molero, CEO of 3PBIOVIAN, *"The true strength of our company lies in our people, who have worked tirelessly to create an environment of excellence focused on the customer and their manufacturing needs. We are deeply grateful to everyone who has contributed to our success."*

Challenges and Future Goals

Looking ahead, 3PBIOVIAN is committed to continuing its mission of helping clients in the development and manufacturing of therapies that will transform the medicine of tomorrow.

To achieve this, the company has a strategic investment plan for the coming years aimed at addressing the challenges of the competitive industry in which it operates. This includes reinforcing and expanding the capabilities of its business lines – proteins and advanced therapies – expanding its offerings to the United States, and consolidating itself as a leading CDMO in the market.

3pbiovian.com | business@3pbiovian.com

About 3PBIOVIAN

3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. Their service offerings include protein expression and production platforms based on microbial strains and mammalian cells, plasmid DNA, viral vectors for adenovirus and adeno-associated virus for gene therapy, and cell therapy products. Additionally, they provide fill and finish services for recombinant proteins and viral vectors. The company has manufacturing facilities in Pamplona-Noáin, Spain, and Turku, Finland, efficiently supporting the diverse needs of their clients, covering everything from preclinical and clinical supply to large-scale commercial manufacturing for drug substance and drug product. www.3pbiovian.com

MEDIA CONTACTS

Spain

Edurne Gil
Head of Marketing and
Communication
egil@3pbiovian.com
Phone: [+34 948 34 64 80](tel:+34948346480)

Finland

Taru Värri
Marketing Manager
taru.varri@3pbiovian.com
Phone: [+358 50 3650973](tel:+358503650973)